Myriad Genetics
MYGN
234 hedge funds and large institutions have $3.41B invested in Myriad Genetics in 2015 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 74 increasing their positions, 89 reducing their positions, and 31 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
9% more capital invested
Capital invested by funds: $3.13B → $3.41B (+$282M)
3% more call options, than puts
Call options by funds: $33.7M | Put options by funds: $32.7M
0% more funds holding
Funds holding: 234 → 234 (0)
0% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 31
17% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 89
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.2M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$17.5M |
| 3 |
D.E. Shaw & Co
New York
|
+$17.3M |
| 4 |
RCMC
RK Capital Management (Colorado)
Denver,
Colorado
|
+$15.1M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$28.5M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$22.8M |
| 3 |
RA
Royce & Associates
New York
|
-$19.6M |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$18.6M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$18.6M |
MYGN Hedge Fund Activity: Q3 2015 in Review
234 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2015, worth a combined $3.41B — up 9% from $3.13B a quarter earlier.
Fund positioning in MYGN was balanced in Q3 2015: 31 funds opened new positions, 31 closed out, 74 added to existing stakes and 89 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $31.2M. The largest seller was Manulife (Manufacturers Life Insurance), cutting an estimated $28.5M.
- 234 institutional investors held Myriad Genetics (MYGN) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $3.41B of Myriad Genetics stock for Q3 2015, up 9% quarter-over-quarter.
- 31 funds opened new Myriad Genetics positions in Q3 2015 and 31 closed out, a net change of 0 holders.
- The largest Myriad Genetics buyer in Q3 2015 was Fidelity Investments, an estimated $31.2M added.
- The largest Myriad Genetics seller in Q3 2015 was Manulife (Manufacturers Life Insurance), an estimated $28.5M sold.
Based on aggregated 13F filings for Q3 2015.